ACRV Stock Summary and Trading Ideas (Acrivon Therapeutics | NASDAQ:ACRV)

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Acrivon Therapeutics trades on the NASDAQ stock market under the symbol ACRV.

As of April 24, 2024, ACRV stock price declined to $9.50 with 168,077 million shares trading.

ACRV has a beta of 0.62, meaning it tends to be less sensitive to market movements. ACRV has a correlation of 0.01 to the broad based SPY ETF.

ACRV has a market cap of $293.28 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that ACRV belongs to (by Net Assets): IWM, VTI, IWN, VXF, CNCR.

ACRV has underperformed the market in the last year with a price return of -21.6% while the SPY ETF gained +24.1%. However, in the short term, ACRV had mixed performance relative to the market. It has outperformed in the last 3 months, returning +135.7% vs +4.5% return in SPY. But in the last 2 weeks, ACRV shares have been beat by the market, returning -8.6% compared to an SPY return of -1.7%.

ACRV support price is $8.96 and resistance is $10.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRV stock will trade within this expected range on the day.